Johnsen U L, Lyberg T, Galdal K S, Prydz H
Thromb Haemost. 1983 Apr 28;49(2):69-72.
Human umbilical vein endothelial cells in culture synthesize thromboplastin upon stimulation with phytohaemagglutinin (PHA) or the tumor promotor 12-O-tetradecanoyl-phorbol-13-acetate (TPA). The thromboplastin activity is further strongly enhanced in a time dependent reaction by the presence of gel-filtered platelets or platelet aggregates. This effect was demonstrable at platelet concentrations lower than those normally found in plasma, it may thus be of pathophysiological relevance. The thromboplastin activity increased with increasing number of platelets added. Cycloheximide inhibited the increase, suggesting that de novo synthesis of the protein component of thromboplastin, apoprotein III, is necessary. When care was taken to remove monocytes no thromboplastin activity and no apoprotein III antigen could be demonstrated in suspensions of gel-filtered platelets, platelets aggregated with thrombin or homogenized platelets when studied with a coagulation assay and an antibody neutralization technique.
培养的人脐静脉内皮细胞在用植物血凝素(PHA)或肿瘤促进剂12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)刺激后会合成凝血活酶。在凝胶过滤的血小板或血小板聚集体存在的情况下,凝血活酶活性会在时间依赖性反应中进一步强烈增强。这种效应在血小板浓度低于血浆中通常发现的浓度时即可显现,因此可能具有病理生理学相关性。凝血活酶活性随着添加的血小板数量增加而增加。环己酰亚胺抑制了这种增加,表明凝血活酶蛋白成分脱辅基蛋白III的从头合成是必要的。当小心去除单核细胞时,在用凝血测定法和抗体中和技术研究时,凝胶过滤的血小板、与凝血酶聚集的血小板或匀浆血小板的悬浮液中均未显示出凝血活酶活性和脱辅基蛋白III抗原。